Home | Structured Search | Drug Resource
Find: within
Cellulitis and Soft Tissue Infections > Drug Therapy Author: Dennis L. Stevens, PhD, MD; Lawrence J. Eron, MD, FACP
Editorial changes - 2009-11-03
Author information and module status
Prevention
Screening
Diagnosis
Consultation for Diagnosis
Hospitalization
Non-drug Therapy
Drug Therapy
Patient Education
Consultation for Management
Follow-up

Tables
Figures
References
Glossary
What's New
Patient Information
Additional Resources
Tools

Rationale:

  • Oral therapy is adequate treatment for most mild, uncomplicated infections.

Evidence:

  • The efficacy of cephalexin is equivalent to that of dicloxacillin in the treatment of children with skin infections caused by S. aureus (86).
  • Patients treated with cephalexin should be observed for failure. In some studies a high failure rate has been observed for cephalexin compared with other β-lactam antibiotics in the treatment of uncomplicated outpatient cellulitis in adult patients (87). Such failures may result from poor absorption due to achlorhydria (33; 81).
  • Cefuroxime is effective treatment of soft tissue infections associated with bacteremia in children (87).
  • Oral linezolid is equivalent to intravenous oxacillin/oral dicloxacillin in adults with complicated soft tissue infections (88).
  • Frequent recurrences have been prevented by long-term administration of prophylactic antibiotics (89). In patients with chronic lymphedema, selenium has been effective in one study in preventing recurrences (90).

Comments:

  • Because of its cost, linezolid should only be used for moderate to severe MRSA infection.
  • Use of gatifloxacin is contraindicated in diabetic patients due to the higher risk of hyperglycemia and hypoglycemia, and should be used cautiously in older patients and those with renal insufficiency.

FAQs
Dennis L. Stevens, PhD, MD has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations. Lawrence J. Eron, MD, FACP has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations.
Darren B. Taichman, MD, PhD, Editor, PIER, has received grant support from Actelion Pharmaceuticals Ltd , and honoraria for continuing medical education grand rounds and lectures given.


The information included herein should never be used as a substitute for clinical judgment and does not represent an official position of ACP. Because all PIER modules are updated regularly, printed web pages or PDFs may rapidly become obsolete. Therefore, PIER users should compare the date of the last update on the website with any printout to ensure that the information being referred to is the most current available.
PIER is copyrighted (c) 2010 by the American College of Physicians,
190 N. Independence Mall West, Philadelphia, PA 19106-1572, USA.